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Abstract
Aim: To study the dose-response of stage I non-small-cell lung cancer (NSCLC) in terms of long-term local tumor
control (LC) after conventional and hypofractionated photon radiotherapy, modeled with the linear-quadratic (LQ)
and linear-quadratic-linear (LQ-L) approaches and to estimate the clinical α/β ratio within the LQ frame.
Material and methods: We identified studies of curative radiotherapy as single treatment through MedLine search
reporting 3-year LC as primary outcome of interest. Logistic models coupled with the biologically effective dose
(BED) at isocenter and PTV edge according to both the LQ and LQ-L models with α/β = 10 Gy were fitted.
Additionally, α/β was estimated from direct LQ fits.
Results: Thirty one studies were included reporting outcome of 2319 patients. The LQ-L fit yielded a significant
value of 11.0 ± 5.2 Gy for the dose threshold (Dt) for BED10 at the isocenter. The LQ and LQ-L fits did not differ
substantially. Concerning the estimation of α/β, the value obtained from the direct LQ fit for the complete
fractionation range was 3.9 [68 % CI: 2.2–9.0] Gy (p > 0.05).
Conclusion: Both LQ and LQ-L fits can model local tumor control after conventionally and hypofractionated
irradiation and are robust methods for predicting clinical effects. The observed dose-effect for local control in
NSCLC is weaker at high doses due to data dispersion. For BED10 values of 100–150 Gy in ≥3 fractions, the
differences in isoeffects predicted by both models can be neglected.
Keywords: Non-small cell lung cancer, Dose-response modeling, Biologically effective dose, Linear-quadratic model,
Alpha-beta ratio
Introduction
The linear-quadratic (LQ) model was developed to
describe experimental survival curves of both normal
and tumor cells after irradiation. The LQ model fits
the cell surviving fraction through a second-order
polynomial on the dose per fraction, with coefficients
α and β. The ratio between both coefficients describes
the repair capacity of the cells and thus sensitivity to
fractionation [1, 2].
The LQ model provides an accurate description of
fractionation effects at doses between 1 and 8–10 Gy
per fraction [3]. Essentially, this formalism enables iso-
effect calculations in current clinical practice, defining
the relationships between the biological irradiation effect
and key parameters such as dose per fraction, total num-
ber of fractions and treatment time. Advancements in
this model led to the two most extended, complemen-
tary approaches for isoeffect calculation: the biologically
effective dose (BED) and the equivalent dose in 2 Gy per
fraction (EQD2) [4].
Current treatment of choice for stage I non-small cell
lung cancer (NSCLC) is surgical tumor extraction. Since
it became technically feasible, radiotherapy has been
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used as an alternative treatment method in inoperable
cases. Early approaches used 3D-conformal convention-
ally fractionated techniques, whereas today, stereotactic
body radiotherapy (SBRT) allows for highly precise
delivery of radiation, thus enabling hypofractionation to
deliver ablative radiation doses in 1–5 fractions [5].
Therefore, SBRT evolved to be the current treatment of
choice for early-stage NSCLC in medically inoperable
patients and in patients who do not consent to surgery.
The high precision of dose delivery facilitates normal tis-
sue sparing, even allowing for dose escalation to poten-
tially improve local control. Despite a growing pool of
clinical outcome data, the optimal total dose and frac-
tionation scheme to reach the intended biological effects
in terms of both local tumor control and side effects are
still under debate [6].
Hypofractionation requires reliable isoeffect calcula-
tions. Thus, the relevance of the question has been
renewed, whether the description of radiobiological ef-
fects based on the LQ formalism is appropriate for
hypofractionated treatments [7–9].
If no α/β ratio estimation is available for a specific
tumor entity, a generic value of 10 Gy is used for BED
calculations, although the precision achievable with such
a standard α/β ratio is assumed to be lower. Numerous
attempts to calculate clinical α/β values have been made,
using available clinical outcome data [10]. Such estima-
tions are specially needed if the α/β of a specific tumor
entity is suspected to be lower than 10 Gy. In this case a
modified fractionation scheme, which reduces tumor cell
recovery between fractions, could increase the thera-
peutic ratio as is the case e.g. in prostate carcinoma or
breast cancer.
Many recent studies aim at outcome review and
modeling of the dose response relationship of NSCLC
[11–15]. However, studies attempting to estimate the α/
β ratio for NSCLC are scarce [11, 15, 16]. It is subject of
current debate if the improved outcomes of hypofractio-
nated SBRT are a consequence of an α/β ratio lower
than 10 Gy, or even lower than the α/β value of the
surrounding normal tissue, which could add a radiobio-
logical rationale to the use of hypofractionation. Alterna-
tively, the improvement could be caused by a reduced
repopulation in a shorter overall treatment time.
In addition, in particle radiotherapy, a currently emer-
ging field in radiation oncology, radiobiological consider-
ations are of importance. For proton radiotherapy
hypofractionated concepts are aimed for partially as
motion management strategy [17–20], so that isoeffect
calculations are essential. Apart from isoeffect calcula-
tions current treatment planning strategies for light ion
therapy also require the attribution of radiobiological
properties to both tumor and normal tissues. Specific-
ally, in scanned-beam carbon ion therapy, radiosensitivity
is characterized through α/β values obtained from photon
irradiation experiments in vitro [21] in one of the math-
ematical models describing the enhanced biological effect
in the Bragg peak, the so called local effect model (LEM),
which is implemented in commercial treatment planning
systems.
In such situation, clinical long time follow up data is
the most valid source of data for modeling approaches,
which is however inherently limited by inhomogeneity
of treatment parameters and treatment techniques
evolving over time. We focused our analysis on the com-
parison of the LQ-L versus the LQ model, since most of
the mathematical model corrections to the LQ model
proposed need additional input parameters [16, 22–24],
which are not available for the specific clinical situation.
Therefore, this work aims at:
1) investigating the dose-response of NSCLC tumor
control data from conventionally fractionated (CF)
and stereotactic, hypofractionated radiotherapy
treatments (HF), based on a review of published
long-term outcome results,
2) evaluating the validity of the LQ and LQ-L models
for both conventional and SBRT treatments,




We identified inclusion criteria, search strategy, outcome
measures of interest and indispensable treatment param-
eters for the study. The analysis keeps standards of the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statements [25].
Selection criteria
PubMed was searched (July 2015) without restrictions
on the publication date. Abstracts of conference pro-
ceedings were excluded and language was restricted to
English. Repeated publications based on the same cohort
were excluded as were outcome reviews in order to
avoid duplicity of cohorts. The selection of studies based
on the following criteria was made by two independent
researchers.
Study cohorts were eligible only if the following cri-
teria were fulfilled:
1) Patients with stage I NSCLC (cT1/2, cN0, cM0)
with either central or peripheral tumor location.
2) Treatment with photon radiotherapy with curative
intent either 2D or 3D-conformal radiotherapy or
SBRT as single modality treatment. Treatment could
be delivered with CyberKnife, GammaKnife or linac-
based without restrictions on fractionation schemes
Santiago et al. Radiation Oncology  (2016) 11:67 Page 2 of 13
(e.g. normofractionated, accelerated, hyper- or hypo-
fractionated schedules, single fraction irradiation),
provided complete information on number of frac-
tions, dose per fraction, total absorbed dose and
overall treatment time was available.
3) Reported outcome of interest (actuarial 3-year local
control estimations according to Kaplan-Meier or
other methods, in which death was a censored
event) with a median follow-up time in each cohort
≥17 months.
4) From an original study (i.a. prospective randomized
controlled trial or prospective or retrospective
observational study or case series).
5) The reported cohorts must include at least 25
patients.
6) Patients could be judged to be either operable or
inoperable if the clinical decision was made in favor
of radiotherapy.
7) A small amount of heterogeneity in reported dose
and patient parameters for a given outcome data
point was accepted (e.g. a marginal group of patients
treated with a deviating radiation scheme, or a small
proportion of tumors included in the report of a
stage I population with clinical staging other than I).
Data extraction
The main endpoint of this review was local tumor
control (LC) at 3 years. If this value was not explicitly
provided in the text, it was extracted from the Kaplan-
Meier diagrams.
The fractionation concept (dose per fraction, number
of fractions and total treatment time), and the planning
technique were extracted together with further treat-
ment- and patient-related parameters. The range of
variation in reported cohort parameters for each local
tumor control data point was qualitatively assessed and
highly heterogeneous cohorts were excluded. Reported
mean or preferably median dose values were used to de-
scribe the outcome of each specific patient cohort. All
prescription doses were translated to doses at the iso-
center and at PTV edge, calculated according to the
information provided in each publication (more details
in the Additional file 1). Mathematical modeling was
performed with both, doses at the isocenter and at the
PTV edge. The treatments were classified to be hypo-
fractionated (HF) if 1–10 fractions were delivered
with doses per fraction at the isocenter above 6 Gy.
Treatments were classified as conventionally fraction-
ated (CF) with a broader definition than in the
clinical convention, based on the validity limits of the
LQ model according to our current knowledge,
namely treatment delivered in more than 10 fractions
with fraction doses at isocenter ranging between 1.2
and 6 Gy.
Data analysis and mathematical models
Model parameters were fitted with nonlinear least
square optimization methods and confidence intervals
were calculated with likelihood profiling. A logistic rela-
tionship between tumor control probability (TCP) and
the biological effective dose (BED) was assumed, accord-
ing to the parameterization described in Okunieff et al.
[26] and Bentzen et al. [27]. BED was based on the LQ
model, calculated from the number of fractions and the
dose at the isocenter, taking into account neither re-
population nor hypoxia, according to Eq. 1:












where TCD50 is the dose necessary to obtain a local
tumor control of 50 % and k is a parameter with dose
units that is used to calculate the normalized slope, γ50.
This parameter quantifies the change in the expected
TCP when a 1 % change in dose occurs, evaluated at the
dose level of the TCD50, and represents the maximal
slope of the dose-response relationship. It can be calcu-





The same logistic model was implemented with an
alternative BED definition, including a transition from
linear-quadratic dependence for the cell survival to
purely linear beyond a certain dose level, the dose
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where n is the number of irradiation fractions, d is the
fraction dose, and Dt is the threshold for the fraction
dose.
The LQ and LQ-L models were fitted to the joint
dataset, and to the CF and HF subsets separately, for
BED doses calculated both at the isocenter and the
PTV edge. First, the linear-quadratic (LQ) model was
applied with α/β fixed to 10 Gy, as it is universally
accepted for conventional fractionation. The alterna-
tive BED definition derived from the LQ-L model was
also applied with α/β equal to 10 Gy, to test if the
inclusion of a dose threshold Dt would improve the
previous fit. Additionally, a study to tentatively
Santiago et al. Radiation Oncology  (2016) 11:67 Page 3 of 13
estimate the α/β ratio from these clinical data was
carried out.
In summary, the following fits were calculated:
1) LQ model with α/β ratio fixed to 10 Gy on the full
dataset, and on the HF and CF datasets separately.
2) LQ-L model with α/β ratio fixed to 10 Gy on the
full and on the HF datasets.
3) LQ model with free γ50, TCD50 and α/β ratio on the
full and the CF datasets.
Finally, in order to compare with the results of the re-
cent analysis of Chi et al. [15] the Spearman’s correlation
between 3-year LC and BED calculated with different
fixed α/β ratios was also investigated on the full and on
the HF datasets.
The quality of the fits was assessed with checks of
the residuals for normality. Models were ranked
according to the Akaike Information Criterion (AIC),
and for the LQ and LQ-L, being nested models, max-
imum likelihood ratio tests were made. All fitted and
calculated values are reported together with their 68
% confidence intervals (CI), whenever possible. Statis-
tical significance was assumed for p values < 0.05.
Data handling, statistical analysis, model fitting and
graphing were done with the software package R,
version 2.15.0 [29].
Results
Selected patient cohorts and description of the studies
In total, 31 studies were identified, which fulfilled the
selection criteria, Of those, 8 studies report outcomes after
conventionally fractionated treatments of a total of 344
patients [30–37] and 23 studies including 1975 patients
reporting on hypofractionated irradiations [38–60]. A total
of 34 local control - schedule data points, with doses per
fraction ranging from 30 to 1.2 Gy, applied in 1–58 frac-
tions, were collected (see Tables 1 and 2, and Additional
file 1 for details of the publication search).
Of all reported tumors, 63.6 % were confirmed to be
stage T1, 36.4 % T2 (Table 3). A total of 68.1 % of
tumors were histologically confirmed: 45.8 % adenocar-
cinomas, 34.1 % squamous cell carcinomas, 6.2 % other
histologies and 13.9 % carcinoma not otherwise specified
(NOS). Of the patients treated with conventional frac-
tionation 86.3% were confirmed medically inoperable,
versus 55.2 % of all patients treated with hypofractio-
nated schedules. Median of the reported median ages
[age range] was comparable between both groups,
namely 72 [range: 35–90] and 75 [range: 29–94] years in
the CF and HF groups respectively. Patients, who re-
ceived conventionally fractionated RT were treated in
the time period from 1976 to 2010, whereas patients
treated with hypofractionated regimes were irradiated in
the time period from 1996 to 2012. In the CF cohort
only in one study PET-CT was performed for staging in
6 out of 31 patients (Bogart et al. [36]), whereas for
many of the HF cohorts PET was a routine procedure;
for many of the most recent studies PET-staging was
even an inclusion criterion in the retrospective series.
In the 8 series of the CF group, generally a margin of
1–1.5 cm was added around the gross tumor volume
(GTV), which was in some cases estimated from port
films if no planning computer tomography (CT) scan
was available. In the HF series, most frequently no
GTV-to-CTV (clinical target volume) margins were
added, except in 5 out of 23 series. Internal target vol-
ume (ITV) concepts were applied in 13/23 studies, based




















D [Gy] d [Gy] T [d]
1 Kaskowitz 1993 [30] 53 20–33 63 (40–80) conventional ns 74.3 69.6 ns 51 ns
2 Jeremic 1997 [31] 49 25–24 69.6 1.2 (2× day) 40 78.0 70.8 ns 55 ns
3 Hayakawa 1999 [32] 36 7–29 60–81 2 48 80.4 75.7 no dens corr 72 (36–216)
4 Cheung 2002 [33] 33 18–15 48 4 21 67.2 62.9 dens corr 63 23
5 Langendijk 2002 [34] 46 26–20 70 2 49 84.0 79.1 dens corr 50 36
6 Bradley 2003 [35] 56 31–25 60–84 1.8–2 42–56 83.7 78.6 no dens corr 63 20 (6–72)
7 Bogart 2005 31 19–12 70 2.3–3.7 39 87.5 83.3 ns 83 29
8 Zehentmayr 2015 [36] 40 19 (Ia)–21 (Ib) 79.2
(73.8–90)
1.8 (2× day) 30–42 93.5 87.5 ns 91 28.5 (2–108)
Median 43 69.8 2.0 44 82.0 77.2 63 28.5 (2–216)
BED10 biologically effective dose with α/β = 10 Gy, PTV planning target volume, D total dose, d dose per fraction, T total treatment time, LC local control, ns
not specified
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d [Gy] T [d]
9 Onimaru
2003 [38]
25 17–8 48/60 6/7.5 14 76.8 56.8 dens inhom corr 55 18 (2–44)
10 Xia 2006 [39] 25 ns 50 5 14 200 75 GammaKnife, ns 96 27 (24–54)
11 Fritz 2008 [40] 40 22–18 30 30 1 120 81.6 modified Batho 81 20 (6–62)
12 Onimaru
2008 [41]
41 13–28 40/48 10/12 5 105.6 75.3 ns 57 27 (9–62)
13 Baumann
2009 [42]
57 40–17 45 15 5
(4–15)
211.2 112.5 PB, dens inhom corr 92 35 (4–47)
14 Brown 2009 [43] 31 20–11 60–
67.5
3–5 5 347.5 180.0 ns 86 28 (24–53)
15 Fakiris 2009 [44] 70 34–36 60/66 20/22 5 309.4 211.2 no dens inhom corr 88 50 (1–65)
16 Kopek 2009 [45] 88 51–36 45/
67.5





56 42–14 50 10 11
(8–14)
168 100.0 dens inhom corr 97 20 (2–48)
18 Baba 2010 [47] 124 87–37 48/52 12/13 11 105.6/
119.6




76 57–19 54 18 8–14 219.4 151.2 Trilogy, ns 89 19
20 Timmerman 2010
[49]
55 44–11 54 18 14 286.4 151.2 dens inhom corr 98 34 (5–50)
21 Videtic
2010 [50]
26 22–6 50 10 5 112.3 100 dens inhom corr 94 31 (10–51)
22 Andratschke
2011 [51]
92 31–61 24/45 3/5 5–12 192.2 84.4 dens inhom corr 83 21 (3–87)
23 Hamamoto
2012 [52]





177 106–71 60 12 20
7.5
14 187.5 132.0 Brainlab, ns 93 32
Shibamoto
2012 [54]
75.3 PB convo, Batho 83 36
25a Shibamoto, d2 124 124 T1 48 12 9–21 105.6 75.3 86
25b Shibamoto, d3 52 52 T2 52 13 9–21 119.6 84.9 73
Shirata 2012 [55] 63–18 89.9 PB convolution Batho 89 30 (0.3–79)
26a Shirata, d1 45 48 12 105.6 89.9 100
26b Shirata, d2 29 60 7.5 105 91.4 82
Takeda 2012 [56] XiO/CMS, CS
27a Takeda, d1 27 10–17 40 8 5 100 72.0 72 21 (6–64)
27b Takeda, d2 138 91–47 50 10 5 140.6 100.0 87 21 (6–64)
28 Inoue 2013 [57] 109 79–30 45/48 15/12 4–7 105.6 75.3 dens inhom corr 81 25 (4–72)
29 Takeda 2013 [58] 109 67–42 40/50 8/10 5 140.6 100 convolution-
superposition
84.4 24 (3–65)
30 Hamaji 2015 [59] 104 75–29 48 12 5 105.6 75.3 PB convol, Batho 76.7 43 (6–115)
31 Rwigema [60] 46 - 54 18 5 234.5 151.2 MC 95.5 16.8 (0.6–38.9)
Median 57 56.0 12.5 7 119.8 89.9 86 27.0 (0.3–115)
BED10 biologically effective dose with α/β = 10 Gy, PTV planning target volume, D total dose, d dose per fraction, T total treatment time, LC local control, ns not
specified, dens inhom corr density inhomogeneity correction, PB convol pencil beam convolution, CS convolution superposition
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either on addition of GTV from 3D-CT scans in expir-
ation/inspiration and free breathing in 4 cases, on slow
CT scans in 5 cases, and on 4D-CT scans in 4 cases.
Nine out of 23 studies did not apply any ITV concept.
The most frequently used CTV-to-PTV (planning target
volume) margins were 0.5 cm in axial and 1 cm in
cranio-caudal directions. A minimal margin of 0.2 cm
was added in one patient cohort treated with the Cyber-
Knife where tumor tracking was used to correct for
intrafractional target motion. In 2 out of 23 series the
PTV margin definition was patient-specific.
Different dose reporting concepts were found through-
out the selected references. Only 5 CF reports out of 8
explicitly mentioned that the dose was prescribed to the
isocenter. When not specified, prescription to the iso-
center was assumed. In the case of the hypofractionated
SBRT data, 9 references reported the prescribed dose to
isocenter and 11 to the isodose line encompassing the
PTV, which ranged from the 50 to the 100 % isodose,
most frequently to the 80 % isodose line. Only one of
the SBRT cohorts was treated with IMRT, and in this
case the dose was prescribed to the 95 % isodose line en-
closing the PTV. More information can be found in the
Additional file 1.
Median [min - max] applied BED at the isocenter, cal-
culated with an α/β ratio of 10 Gy (BED10), was 82.0
[67.2–93.5] and 119.8 [76.8–347.5] Gy for the CF and
HF groups, respectively. At the PTV edge, values of 77.2
[62.9–87.5] and 89.9 [56.8–211.2] Gy were applied in the
CF and HF groups.
Median value of the documented median follow-up
times were 28.5 and 27 months for the CF and HF
groups, respectively. Very few of these publications
state explicitly the number of patients at risk at each
follow-up time point (four cohorts). In only 5 of the
selected studies an estimation of the 95 % CI of the
calculated actuarial local control rates was reported
and one publication presents the standard error.
Therefore, no information could be collected about
the precision of the estimated actuarial local control
rates, apart from the cohort size and the median
follow-up time.
3- and 5- year clinical outcomes for stage I NSCLC
The median value [range] for the 3-year LC was 86
[range: 55–100] % for the HF, and 63 [range: 50–91] %,
for the CF series, respectively. Twenty-two out of 26 HF
3-year LC data points lie above the 80 % level, while all
except two of the CF datasets lie below. All except one
HF treatments delivered a BED10 of 100 Gy or higher at
the isocenter but none of the CF treatments reached a
BED10 of 100 Gy.
Spearman’s correlation coefficients between dosimetric
parameters (total absorbed dose and BED10) and the dif-
ferent clinical outcomes were calculated. For the
complete dataset and the total BED10 at the isocenter, a
significant Spearman’s correlation of 0.716 for the local
control with BED10 was found. For the BED10 evaluated
at the PTV edge, a significant correlation of 0.638 was
found between LC and BED10. The total absorbed dose
at either dose point however did not correlate with LC.
Modeling local control versus BED
Linear-quadratic (LQ) model with α/β ratios fixed to 10 Gy
(two-parameter fit)
All 3-year LC data points for both the HF and CF treat-
ments were fitted to a logistic model coupled with
BED10 at both isocenter and PTV edge. For the isocen-
ter, the TCD50 [68% CI] was 48.3 [23.8–62.4] Gy, k was
44.7 [32.1–64.8] Gy, and the calculated γ50 (std error)
was 0.27 ± 0.1. A logistic fit under the same assumptions,
based on the CF subset alone was made, and resulted in
the values: TCD50 of 68.9 [50.7–74.4] Gy, k was 20.5
[13.1–50.0] Gy and γ50 was 0.84 ± 0.5. The same ap-
proach applied to the HF dataset showed a TCD50 of
−60.2 [−189–3.2] Gy, k of 113.3 [73.4–190.1] Gy, and
γ50 of −0.13 ± 0.17. These three logistic models are rep-
resented in Fig. 1a, and all fit parameter values are sum-
marized in Table 5. The p value was found to be < 0.05
for both TCD50 and k simultaneously only for the model
based on the full dataset.
The model for the complete dataset based on BED10 at
PTV edge yielded a TCD50 of 28.0 [−0.7–43.1] Gy, and k
was equal to 39.7 [28.1–60.5] Gy. These values were
64.2 [48.6–69.3] and 19.5 [12.5–44.6] Gy respectively for

















% Adeno % SCC % NOS % Other
CF 344 48.0 % 26.3 47.0 15.5 11.2 11.6 86.3 72 (35–90) 28.5 (2–216) 82.0 (67.2-93.5) 43 (31–56)
HF 1975 66.3 % 50.4 31.1 13.5 5.0 35.9 55.2 75 (29–94) 27 (0.3–115) 119.6 (76.8–347.5) 57 (25–177)
Total 2319 63.6 % 45.8 34.1 13.9 6.2 31.9 59.8 74 (29–94) 27 (0.3–216) 105.6 (67.2–347.5) 53 (25–177)
Adeno adenocarcinoma, SCC squamous cell carcinoma, NOS carcinoma not otherwise specified, HF hypofractionated treatment regime, CF conventionally
fractionated treatment schedule
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the CF, and −19.9 [−93.5–14.5] and 64.4 [42.9–108.1] Gy
for the HF group alone. Only the parameter values for
the CF dataset yielded significant p values simultan-
eously. Model summaries and calculated γ50 values
together with their standard errors obtained with propa-
gation of uncertainties are also presented in Tables 5.
These models are represented in Fig. 2a.
Linear-quadratic-linear (LQ-L) model with α/β fixed to 10 Gy
(three-parameter fit)
The alternative BED definition including a linear portion
in the dose-effect beyond a certain fraction dose was
tested, according to Eq. 3, with an α/β ratio fixed to 10
Gy. Fits were performed either based on the full dataset
or on the HF subset alone.
For the models based on BED10 at the isocenter, the fit
based on the full dataset generated a Dt value of 11.0
[8.4–16.7] Gy, together with a TCD50 value of 44.7
[24.2–58.2] Gy, and k equal to 46.7 [35.1–63.2] Gy. The
calculated γ50 value was 0.24 ± 0.11. All of the parameter
estimates yielded significant p values. 13 out of 34 data
points represented a dose per fraction below the
estimated Dt. This fit is shown in Fig. 1b, together with
the LQ fit for comparison, and their respective BEDLQ
and BEDLQ-L data points.
For the fit based on the HF dataset alone, Dt was equal
to 9.8 [5.2–15.0] Gy, TCD50 was 1.0 [na-23.8] Gy, and k
equal to 71.4 [54.2–79.6] Gy. Only two data points were
found to be below this Dt, which was too few to obtain a
reliable estimate. Thus, the fit parameters did not produce
significant p values. This fit is shown in Fig. 2b, together
with the LQ fit for comparison.
When BED10 doses at PTV edge were used, similar Dt
values were found, namely, 12.4 Gy for the complete
dataset, and 9.9 Gy for the HF dataset (this fit is shown
in Fig. 2b). Likelihood ratio tests showed no difference
between LQ-L and LQ fits, independently of which
BED10 doses were used, at isocenter or PTV edge (see
Table 5).
Correlation of local control with BED
To complete the modeling study, the correlation of
the 3-year LC with BED under different assumptions
for α/β equal to 5, 8.6, 10, 15 and 20 Gy was investi-
gated (see Table 4). For the complete dataset and
BED10 values at isocenter, a Spearman’s correlation of
0.716 (p < 0.0001) with BED10 was found. For all other
α/β ratios, correlation values increased marginally
from BED5 (r = 0.706) to a maximum at BED10 and
decreased again for BED20 (r = 0.706), in all cases
being significant. The Spearman’s correlations based
on the BED values at the PTV edge decreased with
growing α/β values for the complete dataset, from
0.680 to 0.510, all of them being significant and
consistently lower than the respective values for the
BED10 at the isocenter (see Table 4).
In contrast, for the HF subset, the correlation of the
LC with the same series of BEDα/β at isocenter increased
minimally from 0.575 to 0.618, and also the values for

















CF + HF:                      TCD50 =      48.3  Gy, k     =    44.7 Gy
CF:                               TCD50 =      68.9  Gy, k     =    20.5    Gy
HF:                               TCD50 =  −60.2  Gy, k     =  113.3 Gy
Martel @ 30m:             TCD50 =    101.4  Gy, γ50 =        1.5 %/%
Guckenberger LQ:       TCD50 =      −1     Gy, k     =    80    Gy
TCPlogist ic =
e(BED−TCD50) k
1 + e(BED−TCD50) k
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LQL  CF + HF datasets
LQ    CF + HF datasets
LQL  CF + HF:         TCD50 =      44.7  Gy, k =    46.7  Gy, Dt =  11  Gy
LQ    CF + HF:         TCD50 =      48.3  Gy, k =    44.7  Gy
LQL  HF:                  TCD50 =        1     Gy, k =    71.4  Gy, Dt =    9.8  Gy
LQ    HF:                  TCD50 =  −60.2  Gy, k =  113.3  Gy
Guckenberger LQL: TCD50=       −2     Gy, k =    80     Gy, Dt =  22     Gy
Fig. 1 a Clinical 3-year LC data points for the conventionally fracionated and hypofractionated datasets versus BED10 at isocenter with corresponding
logistic regression fits of the joint CF + HF dataset, and the CF and HF subsets. Previously published related models are included for comparison: Martel
et al. [28] and Guckenberger et al. [61]. b Comparison between the BED10 (isocenter) data points obtained with the LQ and LQ-L fits for the complete
dataset and for the hypofractionated subset. The range of experimental data of every model is shown with a continuous line and the extrapolation
regions with dashed lines. The levels 80 % TCP and 100 Gy BED10 are also shown for reference
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LQ model with three-parameter logistic fit
Additionally, we attempted to estimate the α/β ratio
for NSCLC from the complete data set, fitting all
three model parameters simultaneously: TCD50, k and
α/β. We obtained for the BED doses at isocenter an
α/β value of 3.9 [2.2–9.0] Gy, TCD50 of 17.8 [na-56.4]
Gy, and k of 130.9 [50.1-na] Gy, with only TCD50
yielding a p value < 0.05. For the CF dataset alone we
found a similar α/β of 3.8; however, it was not pos-
sible to determine confidence intervals. These fits are
represented in Fig. 3b. In order to check plausibility
of the fit results and to compare our results with
published values we calculated γ50 and found a value
of 0.0 ± 0.15. For the models based on BED10 at PTV
edge we found values for alpha/beta of 1.7 [1.3–4.1]
Gy for the complete dataset and 4.1 [na] Gy for the
CF dataset with no significant p values (Table 5).
Differences in the prediction of isoeffects
In order to translate the impact of the different BED
model assumptions on clinical treatment schedules we
calculated as an example the doses per fraction which
would be necessary to reach selected BED10 levels at the
isocenter (Fig. 4). Under the assumptions of the LQ
model with α/β values of 8, 10, or 15 Gy and the LQ-L
model at the isocenter with α/β equal to 10 Gy and a Dt
of 11.0 Gy, in order to reach 100 Gy (BED), the max-
imum differences among models for one and two frac-
tions are 10.5 and 4.5 Gy, respectively. Maximal
differences remain below 3.3 Gy for treatments delivered
in 3 or more fractions. For 200 Gy (BED), discrepancies
between models in fraction size increase to 30.1 and
10.5 Gy for one and two fractions, respectively and
remain below 5.6 Gy for 3 fractions and more.
Discussion
Review of clinical outcome data after radiotherapy treat-
ment represents the only possibility to gather long-term
information from large numbers of patients, which could
serve as basis for statistical analysis for radiobiological
modeling. However, this task presents a number of chal-
lenges since these datasets are intrinsically heteroge-
neous. Variability among radiotherapy centers applies to
aspects such as target volume definition, dose prescrip-
tion, planning concepts and delivery techniques with
















CF + HF:                      TCD50 =      28  Gy, k     =    39.7 Gy
CF:                               TCD50 =      64.2  Gy, k     =    19.5    Gy
HF:                               TCD50 =  −19.9  Gy, k     =  64.4 Gy
Guckenberger LQ:       TCD50 =     −35     Gy, k     =    62    Gy
TCPlogist ic =
e(BED−TCD50) k
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LQL  CF + HF datasets
LQ    CF + HF datasets
LQL  CF + HF:         TCD50 =      26.1  Gy, k =    40.8  Gy, Dt =  12.4  Gy
LQ    CF + HF:         TCD50 =      28  Gy, k =    39.7  Gy
LQL  HF:                  TCD50 =        1     Gy, k =    50.9  Gy, Dt =    9.9  Gy
LQ    HF:                  TCD50 =  −19.9  Gy, k =  64.4  Gy
Guckenberger LQL: TCD50=       −6     Gy, k =    45     Gy, Dt =  11     Gy
Fig. 2 a Clinical 3-year LC data points for the CF and HF datasets versus BED10 at PTV edge, with corresponding logistic regression fits of the joint
conventionally and hypofractionated dataset, and the conventionally fractionated and hypofractionated subsets. A previously published related model
is included for comparison, Guckenberger et al. [61]. b Comparison between the BED10 (PTV edge) data points obtained with the LQ and LQ-L fits for
the complete dataset and for the hypofractionated subset. The range of experimental data of every model is shown with a continuous line and the
extrapolation regions with dashed lines. The levels 80% TCP and 100 Gy BED10 are also shown for reference
Table 4 Spearman’s correlations of the local control with the
biologically effective dose at the isocenter and the planning
target volume edge, calculated with different α/β values, for the
complete dataset and exclusively for the hypofractionated
dataset (all of them significant, p > 0.05)
Spearman’s r vs BED @ Isocenter vs BED @ PTV edge
α/β [Gy] All datasets HF All datasets HF
5 0.706 0.575 0.680 0.531
8.6 0.716 0.587 0.680 0.560
10 0.716 0.587 0.638 0.542
15 0.749 0.601 0.572 0.606
20 0.706 0.618 0.510 0.601
BED biologically effective dose, PTV planning target volume
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precise dose-effect modeling are: the use of multiple and
sometimes less appropriate dose calculation algorithms
especially in the case of lung tumors (e.g. with limited
heterogeneity correction), which may lead to mis-
estimation of the absorbed dose. Additionally, outcome
of different tumor stages, dose levels and fractionation
schemes are frequently reported together. Furthermore,
including historical cohorts implies dealing with changes
over time in the standard diagnostic and therapeutic
procedures, e.g. for staging, recurrence assessment and
radiotherapy image guidance.
To counteract this variability, we applied strict inclu-
sion criteria to the selected publications. The analysis is
based on 3-year local control in order to depict the
dose-response in mature outcome data, while maintain-
ing a sufficient number of data points. To our know-
ledge this is one of the largest, most homogeneous
patient collectives among similar studies. Through the
combination of conventionally fractionated and hypo-
fractionated data, a broad range of doses and fraction-
ation schemes is covered, which is a further requirement
in order to achieve conclusive modeling results.
Dosimetric heterogeneity in the PTV can be very
pronounced in dose distributions for stereotactic
treatments, reaching dose differences between isocenter
and PTV edge of up to 50 %. It is not possible to know
a priori, which reported dosimetric parameter will
describe best the dose-effect relationship: the dose at the
PTV edge or the dose at isocenter. Therefore, we calcu-
lated models based on both, isocenter and minimum
target doses. The TCD50 doses estimated for the isocen-
ter doses were in general higher than the ones from the
models at PTV edge.
Variability in the estimated doses at PTV edge could
arise for instance, from variations in the CTV and PTV
margin definitions among institutions, or uncertainties
in the dose calculation methods, which in the case of
outdated, less accurate dose calculation algorithms for
the lung, would produce large dose mis-estimation and
underdosage at the PTV edge.
We calculated the Spearman’s correlations between
outcome parameters and the BED10 evaluated at both
dose specification points and observed that the correla-
tions with BED10 at the PTV edge were without excep-
tion lower than the corresponding correlations based on
BED10 at the isocenter. This could be interpreted as an
indication of the isocenter doses being more robust than
the doses at the PTV edge for retrospective modeling
studies, in agreement with previous studies [61].
The BED10 fits based on the CF data and the complete
dataset differ in both the TCD50 and k values. This can
be explained by the fact that the information required
defining the slope of the dose-response curve and the
TCD50, which together shape the sigmoid region of the
logistic function, is provided by the CF data, where
generally a lower BED was applied. This explains why
TCD50 and k are not consistently determined across
models, which use different input data: CF + HF, or HF/
CF alone. We represented the range of the model input
data and the extrapolation regions in all figures, to stress
that special care must be taken predicting doses in the
extrapolation region.
For comparison, Fig. 1 includes the previously pub-
lished dose-response models of Martel et al. [28] and
Guckenberger et al. [61]. Martel et al. found a TCD50,



















HF:                               TCD50 =  −60.2  Gy, k     =  113.3 Gy
HF, constraint@(0,0):   TCD50 =      75.9  Gy, k     =    21.5 Gy
CF:                               TCD50 =      68.9  Gy, k     =    20.5    Gy
CF, constraint@(0,0):   TCD50 =      71.2  Gy, k     =    16.4 Gy
BEDα β [Gy]









CF + HF dataset vs  BED with a/b =   3.9 Gy
CF + HF dataset vs  BED with a/b = 12.6 Gy
CF + HF:                             a/b =    3.9  Gy, TCD50 =  17.8  Gy, k =  130.9 Gy
CF + HF, constraint@(0,0): a/b =  12.6  Gy, TCD50 =  67.1  Gy, k =  19.3    Gy
Fig. 3 Logistic fits for LC versus BEDα/β at isocenter, with constraint to approach the sigmoidal curves to the coordinate origin, a with α/β fixed
to 10 Gy for the CF and HF datasets separately, and b with three free parameters: α/β, TCD50 and k, for the combined dataset with conventionally
fractionated and hypofractionated treatments. Logistic fits without constraint are provided for comparison
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compiled stage I/II data whereas our dataset included
stage I tumors only. The values for the slope γ50 that we
obtained for the complete dataset and the CF subset are
lower than the value in Martel et al. [28] and further
values in the literature. For instance, Stuschke et al. [11]
reported a value of 1.5, and Okunieff et al. [26] found a
value of 1.6 on average.
Our fit based on the HF data alone shows a shallower
curve than the fits including CF data, since the out-
comes after hypofractionation are well above the inflec-
tion point of the sigmoidal curve. Our HF fit results for
both BED10(isocenter) and BED10(PTV edge) are graph-
ically similar to the findings by Guckenberger et al. [61],
which were based on a multicentric compilation of
individual patient SBRT data.
The LQ-L model was proposed to account for the
experimental observation that curves of the (log cell
survival) versus radiation dose often show a more
straightened portion at doses beyond 10 Gy than pre-
dicted by the LQ model. This effect is in the majority of
cases due to heterogeneity of the radiosensitivity distri-
bution of the cells. This is partly due to differences in
the stage of cells in the proliferation cycle, but can also
be due to partially hypoxic conditions. Resistant cells
tend to survive even at larger doses, which causes the
survival curve to become less steep than predicted by
the LQ model. This explanation implies that the
straightening in the curve is not caused by a fundamen-
tal mechanism but by a simple to explain heterogeneity
in the distribution of sensitivity. Both models converge
at dose of less than about 6 Gy.
Applying state-of-the-art fitting methods to compare
the performance of the LQ versus the LQ-L models for
different fractionation schemes, we did not find signifi-
cant differences. Therefore, it was not possible to decide,
which model better predicts clinical NSCLC outcome
Table 5 Summary of the models for both BED doses calculated at isocenter and PTV edge; all fit parameter values are provided
with standard errors (and 68 % CI). This table includes the maximum likelihood ratio tests for comparison between the













AIC Likelihood ratio test LQ vs LQL:
Dataset, Df, LogLik, Df, Chisq, Pr (>Chisq)
ISOCENTER
LQ fixed α/β CF
+ HF




0.27 (0.1) −4438.1 Isocenter, all data 4, 2223.8, 1, 3.42,
0.064




0.84 (0.5) −186.4 -




−0.13 (−0.17) −2625.2 Isocenter, HF 4, 1316.4, 1, 1.68, 0.195
LQ-L fixed α/β CF
+ HF

























CF 3.8 (na) - 90.7 (na)* 19.7 (na) 1.15 (0.64) −186.6
PTV EDGE
LQ fixed α/β CF
+ HF




0.18 (0.13) −4430.1 PTV Edge, all data 4, 2218.3, 1, 0.614,
0.433









−0.08 (−0.16) −2625.9 PTV Edge, HF 4, 1315.9, 1, 0.009, 0.925
LQ-L fixed α/β CF
+ HF

















CF 4.1 (na) - 81 (na) 20.4 (na) 0.99 (na) −186
Dt dose threshold, TCD50 tumor control dose 50 %, AIC Akaike information criterion, Df degrees of freedom, LogLik log-likelihood, Chisq chi-square, PTV planning
target volume
*p value < 0.05
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data. For BED corresponding to doses per fraction below
11.0 Gy, the BED points for both concepts overlap,
whereas above Dt there is a contraction in the BEDLQ-L
values, which has no consequence in the fit itself, since
it takes place in the region where the TCP approaches
100 %. Clinical consequences of using one model or an-
other are only relevant for highly hypofractionated sched-
ules aiming at delivering BED values well above 100 Gy.
The LQ-L model was also fitted to the HF datasets
alone, although we could not obtain a 68 % CI for
the TCD50, and the p values of all three parameters
were > 0.05. Fig. 2b clearly demonstrates the similarity
of our LQ-L fit for the HF data subset to the LQ fit
previously presented, therefore TCP predictions will
be similar with either model. Although our LQ-L fit
based on HF data did not yield significant estimates,
the results suggest a Dt estimate in the same range of
magnitude of 10 Gy. This fit was tested previously
also on hypofractionated data alone by Guckenberger
et al. [61]. Their dataset had a median dose per frac-
tion at isocenter of 20.8 Gy with range [6–41] Gy.
This group found a Dt value of 22 Gy with a broad
68 % confidence interval, [14–42] Gy, whose addition
to the model did not improve the prediction power.
Estimation of the α/β ratio by fitting three parameters
simultaneously on a clinical dataset presenting high
dispersion - as is the case of the current work - is
challenging. Our LQ model with free α/β did not yield
significant values for α/β, nor for TCD50 and the slope k,
which appears to be too shallow after visual inspection.
We concluded that there is no indication for larger α/β
values than 10 Gy if the complete range of fractionations
is considered. The opposite trend (α/β > 10 Gy) was
found for the HF dataset as was also the case in Chi et
al. [15], although no significant p values could be ob-
tained in this case, neither.
There are few works aiming to the estimation of a
clinical α/β for radiotherapy of NSCLC [10, 11, 15].
Thames et al. [10] published an extremely high α/β value
for lung tumors but these authors did not obtain a reli-
able confidence interval and so, their calculations must
be regarded with caution. A similar work was also car-
ried out by Stuschke et al. [11], who found an α/β value
of 8.2 Gy. They used a fit similar to ours, but set a con-
straint to force the model to approach the axes origin by
adding a point with low BED and null TCP, with a high
fit weight. We also tested this approach (full model in-
formation in the Additional file 1), adding a data point
at 0 Gy (BEDα/β) and 0 % TCP. We observed that this
constraint influenced the TCD50 value to a small extent
only, but could have a strong effect on the slope of the
curve, and also on the α/β value, for instance, 3.9 [2.2–
9.0] versus 12.6 [10.5–15.0] Gy for the complete dataset
and BED10(isocenter). The LQ-based fits with α/β of 10
Gy for the CF data alone did not vary much with and
without constraint. In contrast, if the fit was based on
the HF dataset alone, adding this constraint on the ori-
ginal fit had a pronounced effect on the steepness and
TCD50 of the curve, which in the constrained fits
approached the curves based on CF data (Fig. 4a). For
this reason, we think it is preferable not to set a con-
straint to the model, which largely influences the esti-
mates for k and α/β, and also their standard errors. It
seems reasonable to accept that fits done on the HF
dataset alone will not reproduce a realistic fall-off in LC
at low doses nor a plausible, clinical TCD50, since the in-
put dose-response data are well above that region in this
specific case.
The dispersion in the collected data points was high.
Due to this fact, in the hypofractionation range the dose-
effect relationship appears to be weaker than in other re-
ports [13, 61]. Specifically, for the fraction of HF data
above 100 Gy (BED10), the Spearman’s correlation be-
tween LC and BED10 is low. It can be speculated that in
the region of high tumor control probability and highly
hypofractionated treatments the relative contribution of
non-radiobiological factors to the treatment effect is lar-
ger. Such factors are, for instance, subjectivity in target de-
lineation and geographical miss, among others.
The logistic fit was applied also in the study at high
dose regions since it is widely used for dose-effect de-
scription. However, other functional dependencies of LC
with BED might be also appropriate in the high BED
range. Concerning the BED concept, it seems likely that
more than one approach can fit equivalently well on an
inherently noisy dataset like this, for instance the LQ ap-
plying a higher α/β ratio, or the LQ-L model with α/β of
10 Gy, even if these models have contrasting radiobio-
logical implications.





























LQ; α β:   8 Gy
LQ; α β: 10 Gy
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Fig. 4 Fraction dose necessary to deliver a BED equal to 100 and
200 Gy under the assumptions of the LQ model with α/β of 8, 10,
and 15 Gy and LQ-L model with α/β equal to 10 Gy and a Dt value
of 11.0 Gy, estimated for doses at the isocenter
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Conclusion
We found a dose-effect relationship in the studied data-
set, which in the high BED region was weaker due to
considerable dispersion in the data. Both, the LQ and
LQ-L models can be fitted to clinical normo- and hypo-
fractionated NSCLC outcome data. The LQ-L model
yielded a significant value for the Dt of 11.0 Gy for the
model based on BED10(isocenter); however, it produced
a comparable TCP fit to the LQ model. For the applica-
tion of BED10 in the range of 100–150 Gy in three frac-
tions or more, the differences in isoeffects predicted by
both models can be neglected. Our findings therefore do
not allow us to suggest use of the LQ-L model for an
improved fitting compared to the LQ model of local
control data in case of hypofractionation. A tentative
analysis to establish the optimal α/β ratio in the frame of
the LQ model for the full fractionation range did not
produce significant estimates, although, it showed a
trend for α/β values lower than 10 Gy.
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